Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02402309 · ClinicalTrials.gov registry record · Phase 2
A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)
A Phase 2 study of Sjögren-Larsson Syndrome, sponsored by Aldeyra Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 3
- Study locations
NCT02402309 is a Phase 2 study of Sjögren-Larsson Syndrome that has completed, run by Aldeyra Therapeutics. The registered enrollment target is 12 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT02402309, a Phase 2 study of Sjögren-Larsson Syndrome, has completed, sponsored by Aldeyra Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a multi-center, randomized, double-blind, vehicle-controlled, parallel-group study designed to evaluate the safety, pharmacokinetic (PK), and exploratory activity of topically-applied NS2 dermatologic cream administered once-daily (QD) to subjects with ichthyosis secondary to Sjögren- Larsson Syndrome (SLS). NS2 is expected to trap fatty aldehydes that are pathogenic in SLS patients, and thereby diminish the lipid-aldehyde adduct formation that likely results in ichthyosis associated with SLS, and potentially reduce the mild dermal inflammation characteristic of SLS.
Conditions Studied
Interventions
- DRUG Active topical NS2 1% dermatologic cream
- DRUG Vehicle placebo 0.0% NS2 dermatologic cream
Study Locations (3)
Nebraska
- University of Nebraska Medical Center - Omaha
Pennsylvania
- Penn State Hershey Medical Center - Department of Dermatology - Hershey
Virginia
- Pediatric and General Dermatology - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2015-03 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02402309
The ClinicalTrials.gov registry entry for NCT02402309 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aldeyra Therapeutics, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sjögren-Larsson Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Active topical NS2 1% dermatologic cream is the first listed.
NCT02402309 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Nebraska, Pennsylvania, Virginia.
Frequently Asked Questions
What is clinical trial NCT02402309 about?
NCT02402309 is a clinical study titled "A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)". This is a multi-center, randomized, double-blind, vehicle-controlled, parallel-group study designed to evaluate the safety, pharmacokinetic (PK), and exploratory activity of topically-applied NS2 dermatologic cream administered once-daily (QD) to subjects with ichthyosis secondary to Sjögren- Larsso...
What is the current status of trial NCT02402309?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2015-03. Estimated completion is 2016-06.
What conditions does trial NCT02402309 study?
This clinical trial studies the following conditions: Sjögren-Larsson Syndrome.
What interventions are being tested in trial NCT02402309?
The interventions under investigation include: Active topical NS2 1% dermatologic cream (DRUG), Vehicle placebo 0.0% NS2 dermatologic cream (DRUG).
Who is sponsoring clinical trial NCT02402309?
This trial is sponsored by Aldeyra Therapeutics, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02402309 being conducted?
This trial has 3 study locations across Nebraska, Pennsylvania, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.